Zoe Price

Research Interests

Cancer Cell Biology Cancer Diagnosis Cancer Therapy Signal Transduction Cancer Biology and Clinical Oncology

Miss Zoe Price

Research Associate

Centre for Cancer Biology

College of Health

I am currently undertaking a Doctor of Philosophy in the School of Medicine at the University of Adelaide. My project focusses on further understanding the role of hyaluronan, a extracellular matrix glycosaminoglycan, in ovarian cancer. In particular, determining the role of molecular weight of hyaluronan on ovarian cancer stem cell therapy resistance, proliferation, motility and invasion. Additionally, assessing hyaluronan molecular weight ranges as potential prognostic markers for ovarian cancer.

Date Position Institution name
2018 - 2018 Research Assistant University of Adelaide

Date Institution name Country Title
2017 - 2017 University of Adelaide Australia Honours Degree of Bachelor of Health and Medical Sciences
2013 - 2015 University of Adelaide Australia Bachelor of Biomedical Science (Biochemistry and Immunology and Virology)

Year Citation
2025 Shah, M. V., Hung, K., Baranwal, A., Kutyna, M. M., Al-Kali, A., Toop, C., . . . Hiwase, D. K. (2025). Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations. Blood Advances, 9(13), 3370-3380.
DOI Scopus6 WoS4 Europe PMC5
2025 Price, Z. K., Lokman, N. A., Morrison, J., Mhlanga, S. N., Sugiyama, M., Koya, Y., . . . Ricciardelli, C. (2025). Identification of Sphingosine Kinase 1 as a Novel Protein Regulated by High Molecular Weight Hyaluronan in Ovarian Cancer.. J Cell Mol Med, 29(9), e70574.
DOI
2025 Noye, T. M., Mittal, P., Price, Z. K., Fewster, A., Williams, G., Pukala, T. L., . . . Ricciardelli, C. (2025). Identification of Proteins Associated with Ovarian Cancer Chemotherapy Resistance Using MALDI-MSI. International Journal of Molecular Sciences, 26(12), 5893.
DOI
2025 Khetan, R., Lokman, N. A., Eldi, P., Price, Z. K., Oehler, M. K., Brooks, D. A., . . . Albrecht, H. (2025). Protease-Activated Receptor F2R Is a Potential Target for New Diagnostic/Prognostic and Treatment Applications for Patients with Ovarian Cancer. International Journal of Molecular Sciences, 26(17), 8529.
DOI
2025 Lokman, N. A., Macpherson, A. M., Thompson, A. R., Price, Z. K., Goonetilleke, L., Condina, M. R., . . . Ricciardelli, C. (2025). Proteomics analysis of serum extracellular vesicle identifies UCHL1 as a potential therapeutic target for high grade serous ovarian cancer. British Journal of Cancer, 13 pages.
DOI
2023 Varricchio, A., Khan, S., Price, Z. K., Davis, R. A., Ramesh, S. A., & Yool, A. J. (2023). Pharmacological Inhibition of Membrane Signaling Mechanisms Reduces the Invasiveness of U87-MG and U251-MG Glioblastoma Cells In Vitro. Cancers, 15(4), 1-20.
DOI Scopus13 WoS13 Europe PMC10
2023 Price, Z. K., Lokman, N. A., Sugiyama, M., Koya, Y., Yoshihara, M., Oehler, M. K., . . . Ricciardelli, C. (2023). Disabled-2: a protein up-regulated by high molecular weight hyaluronan has both tumor promoting and tumor suppressor roles in ovarian cancer. Cellular and Molecular Life Sciences, 80(11), 1-18.
DOI Scopus6 WoS6 Europe PMC6
2022 Leung, D., Price, Z. K., Lokman, N. A., Wang, W., Goonetilleke, L., Kadife, E., . . . Ahmed, N. (2022). Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial–mesenchymal transition interlinked with reprogrammed metabolism. Journal of Translational Medicine, 20(1), 556-1-556-23.
DOI Scopus25 WoS25 Europe PMC27
2022 Price, Z. K., Lokman, N. A., Yoshihara, M., Kajiyama, H., Oehler, M. K., & Ricciardelli, C. (2022). Disabled-2 (DAB2): A Key Regulator of Anti- and Pro-Tumorigenic Pathways. International Journal of Molecular Sciences, 24(1), 696.
DOI Scopus20 WoS19 Europe PMC19
2019 Lokman, N. A., Price, Z. K., Hawkins, E. K., Macpherson, A. M., Oehler, M. K., & Ricciardelli, C. (2019). 4-Methylumbelliferone inhibits cancer stem cell activation and overcomes chemoresistance in ovarian cancer. Cancers, 11(8), 1-18.
DOI Scopus49 WoS44 Europe PMC37
2019 Mittal, P., Price, Z. K., Lokman, N. A., Ricciardelli, C., Oehler, M. K., Klingler-Hoffmann, M., & Hoffmann, P. (2019). Matrix Assisted Laser Desorption/Ionization Mass Spectrometry Imaging (MALDI MSI) for monitoring of drug response in primary cancer spheroids. Proteomics, 19(21 - 22), e1900146-1-e1900146-4.
DOI Scopus22 WoS20 Europe PMC16
2018 Price, Z., Lokman, N., & Ricciardelli, C. (2018). Differing roles of hyaluronan molecular weight on cancer cell behavior and chemotherapy resistance. Cancers, 10(12), 482-1-482-21.
DOI Scopus73 WoS70 Europe PMC61

Year Citation
2025 Khetan, R., Lokman, N. A., Eldi, P., Price, Z. K., Oehler, M. K., Brooks, D. A., . . . Albrecht, H. (2025). Protease-activated receptor F2R/PAR1 is a potential target for new diagnostic/prognostic and treatment applications for patients with ovarian cancer. In CANCER RESEARCH Vol. 85 (pp. A36). AMER ASSOC CANCER RESEARCH.
DOI
2024 Hung, K., Al-Kali, A., Toop, C., Patnaik, M. M., Price, Z., Kourelis, T., . . . Shah, M. (2024). <i>TP53</i>-Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors. In BLOOD Vol. 144 (pp. 4594-4595). FL, Orlando: ELSEVIER.
DOI WoS2
2024 Hiwase, D., Price, Z., Kok, C. H., Kutyna, M., Singhal, D., Shanmuganathan, N., . . . Scott, H. S. (2024). Pathogenic Germline Variants in the DNA Damage Repair Pathway Are Enriched in Patients with Hematologic Malignancies with Prior Exposure to Cytotoxic Therapies Compared to Patients with Multiple Cancers without Prior Exposure. In BLOOD Vol. 144 (pp. 4596-4597). FL, Orlando: ELSEVIER.
DOI
2024 Shah, M., Hung, K., Baranwal, A., Price, Z., Al-Kali, A., Toop, C., . . . Hiwase, D. (2024). The 66th ASH Annual Meeting Abstract Abstracts. In BLOOD Vol. 144 (pp. 3214). ELSEVIER.

Connect With Me

External Profiles

Other Links